The levels of serum CA50, CA19‐9, and CEA in the BTC patients were higher than those in the HCC, CHC, BBD, and HP patients, and the difference was significant (p < 0.001) (Table 1). The gene discussed is CEACAM5; the disease is hepatocellular carcinoma.